Study wrapper · #924
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS, Welch M, Shah P, et al. Lancet. 2026.
DOI: 10.1016/s0140-6736(26)00967-0PubMed: 42250575
Editor's note
This is a large phase 3 double-blind randomized controlled trial, the strongest tier of clinical evidence for retatrutide in type 2 diabetes. All three doses were associated with significantly greater HbA1c and weight reductions versus placebo, and the safety profile matched other GLP-1-class agents. Two deaths occurred, both reported as unrelated to the study drug; the trial was funded by the manufacturer.
Plain-language abstract
In a phase 3 randomized trial, adults with type 2 diabetes taking retatrutide saw larger reductions in HbA1c and body weight than those on placebo over 40 weeks, with mostly mild-to-moderate gastrointestinal side effects.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026